A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation.

Autor: Scherr CL; Department of Communication Studies, Northwestern University, Evanston, IL, USA. courtney.scherr@northwestern.edu.; Center for Communication and Health, 710 North Lake Shore Drive 15th Floor, Chicago, IL, 60611, USA. courtney.scherr@northwestern.edu., Feuston JL; Department of Communication Studies, Northwestern University, Evanston, IL, USA., Nixon DM; Cancer Genetics Risk Assessment Program, St. Vincent Cancer Center, Indianapolis, IN, USA., Cohen SA; Cancer Genetics Risk Assessment Program, St. Vincent Cancer Center, Indianapolis, IN, USA.
Jazyk: angličtina
Zdroj: Journal of genetic counseling [J Genet Couns] 2018 Apr; Vol. 27 (2), pp. 439-445. Date of Electronic Publication: 2018 Feb 08.
DOI: 10.1007/s10897-018-0222-z
Abstrakt: Professional organizations provide surveillance guidelines for BRCA1 and BRCA2 (BRCA) carriers with intact breasts and/or ovaries to facilitate early cancer detection. However, literature indicates adherence to surveillance guidelines is inconsistent at best. Using the Messaging Model for Health Communication Campaigns framework, we undertook a two-phase formative research approach to develop an intervention to promote adherence to surveillance guidelines. Discussion groups identified preferred intervention format and function in phase I. Findings indicated carriers desired a phone application (app) to assist with surveillance management and appointment tracking. Thus, an iPhone app for carriers to track appointments based on published surveillance guidelines was developed. In phase II, we obtained feedback from BRCA carriers via a survey during a prototype demonstration at a regional conference. Participants in phase II wanted reminder capabilities and the ability to add and modify information fields. This feedback informed intervention modifications, resulting in the Scheduling Necessary Advised Procedures (SNAP) iPhone app currently being pilot tested by BRCA carriers throughout the USA.
Databáze: MEDLINE